Remove Atherosclerosis Remove Pharmacology Remove Plaque
article thumbnail

Computed tomographic angiography measures of coronary plaque in clinical trials: opportunities and considerations to accelerate drug translation

Frontiers in Cardiovascular Medicine

The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional risk factors. Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide.

Plaque 59
article thumbnail

METTL4-Mediated Mitochondrial DNA N6-Methyldeoxyadenosine Promoting Macrophage Inflammation and Atherosclerosis

Circulation

However, the role of METTL4-mediated mitoepigenetic regulation in atherosclerosis is still unknown. We explored the mechanism of METTL4 involvement in atherosclerosis usingMettl4Mac-KO-Apoe-/-andMettl4MUT-Apoe-/-mice and cell models, as well as bone marrow transplantation.

article thumbnail

Atherosclerotic Plaque Erosion: Mechanisms, Clinical Implications, and potential therapeutic Strategies – a review

Journal of Cardiovascular Pharmacology

Atherosclerosis is an insidious and progressive inflammatory disease characterized by the formation of lipid-laden plaques within the intima of arterial walls with potentially devastating consequences. However, despite a heterogenous substrate underlying coronary thrombosis, treatment remains identical.

Plaque 40
article thumbnail

Naturally Occurring Atherosclerosis Progression and In-Stent Restenosis: Exploring Histomorphological Associations Using Optical Coherence Tomography

Journal of Cardiovascular Pharmacology

Nevertheless, the correlation between ISNA and the progression of untreated coronary segments affected by native atherosclerosis remains incompletely investigated. Nevertheless, the correlation between ISNA and the progression of untreated coronary segments affected by native atherosclerosis remains incompletely investigated.

article thumbnail

7 Things You Can Do To Reduce Your Risk Even If You Already Have Heart Disease.

Dr. Paddy Barrett

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. 2004 Mar 3;291(9):1071-80. 4 ASTEROID Investigators. 2006 Apr 5;295(13):1556-65.

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,6 Until recently atherosclerosis has been thought of as the result of passive lipid accumulation in the vessel wall. 4 In the U.S.

article thumbnail

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

DAIC

PAD is a serious, progressive cardiovascular disease primarily caused by a buildup of fatty plaque in the blood vessels, or atherosclerosis. This plaque narrows the blood vessels and reduces blood flow to the legs and feet, which may significantly impair physical function, walking performance and quality of life.